People-Driven Therapeutics
Seattle, WA
Joined November 2018
- Tweets370
- Following158
- Followers2.3K
- Likes230
Variant Bio retweeted
Lux family co @VariantBio
we created + funded this company to find outlier people in outlier parts of the world with outlier traits...
to develop new drugs for all of the rest of us.
Out today on the cover of @ScienceMagazine: work led by @KeoluFox (UCSD) and Alexander Ioannidis (Stanford) with @VariantBio. Polynesians experienced founder effects 10x stronger than Finland’s, with big implications for drug discovery and clinical care: science.org/doi/10.1126/scie…
Variant Bio retweeted
Join our webinar with Dr. Olivia Gray (@VariantBio) tomorrow!
Learn how multiomics revealed mechanisms affecting creatinine-based eGFR estimates in African ancestry populations.
📅 27 May
🕒 11 am EDT | 5 pm CEST
🔗bit.ly/4nIaF1Q
Can genetics bias kidney disease biomarkers?
In our next webinar, Dr. Olivia Gray (@VariantBio) will show how multiomics revealed mechanisms affecting creatinine-based eGFR estimates in African ancestry populations.
📅 27 May
🕑 11 am EDT | 5 pm CEST
🔗 bit.ly/4nIaF1Q
Variant Bio retweeted
Can genetics bias kidney disease biomarkers?
In our next webinar, Dr. Olivia Gray (@VariantBio) will show how multiomics revealed mechanisms affecting creatinine-based eGFR estimates in African ancestry populations.
📅 27 May
🕑 11 am EDT | 5 pm CEST
🔗 bit.ly/4nIaF1Q
Variant Bio retweeted
Alpha in biotech comes from looking where no one else is. At @VariantBio, we’ve built a proprietary engine to uncover human genetic evidence that the rest of the industry is missing. I had a great deep dive into the ethics and science of our approach on @biotechnation today.
Variant Bio retweeted
Thank you for hosting a great conversation on our work @VariantBio, Dr. Moira Gunn! @biotechnation biotechnation.com/episodes/t…
Variant Bio retweeted
@VariantBio and Boehringer Ingelheim are teaming up to advance research focused on kidney diseases
Read the full story here 👇
healthtechnologyinsights.com…
ALT @VariantBio and Boehringer Ingelheim are teaming up to advance research focused on kidney diseases
Variant Bio retweeted
1/ Big news today from Lux family co Variant Bio 🧬📈@VariantBio
Announced its new Inference platform is now available to research partners + has collaborations with several pharmaceutical companies in deals totaling more than $200 million including Boehringer + Novo Nordisk...
Variant Bio retweeted
2/ Variant Bio @VariantBio has just revealed
inference.bio/
the world's first agentic AI genomic discovery platform
Variant Bio retweeted
Harnessing genomics and AI agents in drug discovery, platform underpins new kidney disease collaboration with Boehringer Ingelheim.
longevity.technology/news/va…
#longevity #biotech #drugdiscovery #AI #pharma
Variant Bio retweeted
By combining our AI Inference platform with Boehringer’s expertise, we’re turning global genetic insights into real-world impact for patients. A massive milestone for our team! 🚀
Variant Bio retweeted
Caught @OliviaG_PhD's talk at #ASHG25 and interested in more of @VariantBio's work? Here's a recent publication from Variant in @HGGAdvances on body composition associations in a Malagasy cohort: cell.com/hgg-advances/fullte…
Variant Bio retweeted
Explore our life sciences thesis by Alessandra, Ken, and Elena ↓ generalcatalyst.com/stories/…
Variant Bio retweeted
Since 2021, we’ve invested approximately $700M across more than 30 companies, partnering at every stage—from seed and company creation to public market entry—to seek to drive innovation in this space.
Breakthroughs in biology are converging with advances in applied AI and computational tools, creating new opportunities to tackle complex diseases and improve patient outcomes. Catalyzing transformation at this scale requires uncommon collaboration across science, technology, healthcare, and policy engagement.
Our life sciences thesis focuses on three core areas:
1. Computationally-Enabled Drug Discovery: Treatments powered by computational approaches that address unmet medical needs and have the potential to transform patient care, including those being developed by @manas_co, Parabilis Medicines, and @tahoe_ai
2. Harnessing Nature’s Machinery: Companies leveraging and engineering biological systems to develop novel and effective therapies, including Alpha-9, ArriVent, and @MaxionTx
3. Transforming the Life Sciences Industry: Backing software, services, and tools that underpin scientific research, development, and commercialization across the life sciences, including @aidocmed, @elektrofi, and @ParadigmHLTH
Variant Bio retweeted
Our SABR manuscript is out in Nature Genetics. SABR is the largest functional genomics dataset from a continental African cohort. We mapped the genetic architecture of blood expression, splicing, and cell types in over 600 individuals from 3 SEB groups.
nature.com/articles/s41588-0…
Variant Bio retweeted
There are a number of genomics startups that have sprouted up to strengthen their sequencing technologies to aid in disease prevention and treatment. labiotech.eu/best-biotech/ge…
Variant Bio retweeted
Asst Prof @TrinidadSu56273 discusses ethics research with @KUOW's @RadioGirlMurphy after @VariantBio announces plans for benefit-sharing with indigenous communities for their genetic contributions to drug dev research!
Listen here: kuow.org/stories/seattle-bio…
Variant Bio retweeted
Variant Bio and Novo Nordisk to identify targets for metabolic disease treatment
Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.
pharmaceutical-technology.co…
Variant Bio retweeted
FUTURE OF BIOTECH 👇
Heres' the @nytimes on the unique 'benefit sharing' program pioneered by @variantbio to find OUTLIER people with OUTLIER traits in OUTLIER remote parts of the world.
NYT: "Drug Company to Share Revenues With Indigenous People Who Donated Their Genes"
